Drug-Eluting Stents: Technical and Clinical Progress

Koźlik, Maciej; Harpula, Jan; Chuchra, Piotr; Nowak, Magdalena; Wojakowski, Wojciech; Gąsior, Paweł

doi:10.3390/biomimetics8010072

Cited by 16 publications

(11 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third generation introduced ultrathin struts and advanced biodegradable polymer coating technology ( 63 – 65 ). Each progressive DES generation has witnessed an unceasing evolution of technology and design, all with the collective aspiration of achieving heightened long-term safety and efficacy ( 66 ).…”

Section: Discussionmentioning

confidence: 99%

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

Zeng,

Xu,

Deng

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Drug-eluting stents (DES) play a crucial role in treating coronary artery disease (CAD) by preventing restenosis. These stents are coated with drug carriers that release antiproliferative drugs within the vessel. Over the past two decades, DES have been employed in clinical practice using various materials, polymers, and drug types. Despite optimizations in their design and materials to enhance biocompatibility and antithrombotic properties, evaluating their long-term efficacy and safety necessitates improved clinical follow-up and monitoring. To delineate future research directions, this study employs a bibliometric analysis approach. We comprehensively surveyed two decades' worth of literature on DES for CAD using the Web of Science Core Collection (WOSCC). Out of 5,778 articles, we meticulously screened them based on predefined inclusion and exclusion criteria. Subsequently, we conducted an in-depth analysis encompassing annual publication trends, authorship affiliations, journal affiliations, keywords, and more. Employing tools such as Excel 2021, CiteSpace 6.2R3, VOSviewer 1.6.19, and Pajek 5.17, we harnessed bibliometric methods to derive insights from this corpus. Analysis of annual publication data indicates a recent stabilisation or even a downward trend in research output in this area. The United States emerged as the leading contributor, with Columbia University and CRF at the forefront in both publication output and citation impact. The most cited document pertained to standardized definitions for clinical endpoints in coronary stent trials. Our author analysis identifies Patrick W. Serruys as the most prolific contributor, underscoring a dynamic exchange of knowledge within the field.Moreover, the dual chart overlay illustrates a close interrelation between journals in the “Medicine,” “Medical,” and “Clinical” domains and those in “Health,” “Nursing,” and “Medicine.” Frequently recurring keywords in this research landscape include DES coronary artery disease, percutaneous coronary intervention, implantation, and restenosis. This study presents a comprehensive panorama encompassing countries, research institutions, journals, keyword distributions, and contributions within the realm of DES therapy for CAD. By highlighting keywords exhibiting recent surges in frequency, we elucidate current research hotspots and frontiers, thereby furnishing novel insights to guide future researchers in this evolving field.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

Zeng,

Xu,

Deng

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Studies have shown that the use of BMSs, which do not contain antiproliferative drug layers, is associated with high restenosis rates. A breakthrough in coronary artery stent design was the development of DESs [ 55 ], which are now widely used due to their superior efficacy compared to BMSs. DESs are the preferred choice for percutaneous revascularization because the release of the drug from the polymer coating helps to reduce the risk of restenosis [ 56 ].…”

Section: Medical Devicesmentioning

confidence: 99%

Polymer-Drug Anti-Thrombogenic and Hemocompatible Coatings as Surface Modifications

Zawidlak-Węgrzyńska,

Rydz,

Musioł

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Since the 1960s, efforts have been made to develop new technologies to eliminate the risk of thrombosis in medical devices that come into contact with blood. Preventing thrombosis resulting from the contact of a medical device, such as an implant, with blood is a challenge due to the high mortality rate of patients and the high cost of medical care. To this end, various types of biomaterials coated with polymer-drug layers are being designed to reduce their thrombogenicity and improve their hemocompatibility. This review presents the latest developments in the use of polymer-drug systems to produce anti-thrombogenic surfaces in medical devices in contact with blood, such as stents, catheters, blood pumps, heart valves, artificial lungs, blood vessels, blood oxygenators, and various types of tubing (such as for hemodialysis) as well as microfluidic devices. This paper presents research directions and potential clinical applications, emphasizing the importance of continued progress and innovation in the field.

show abstract

“…However, its non-MRI compatibility and poor visibility in fluoroscopic images do not allow its in vivo placement [ 8 ]. Therefore, to improve the biocompatibility and hemocompatibility properties of stainless steel, coatings are commonly used to modify its surface features, reduce the surface free energy, smoothen the texture, neutralize the surface potential, and improve surface stability [ 8 , 15 ]. Furthermore, drugs can be added, and these modifications reduce thrombosis and neointimal proliferation, which reduces restenosis [ 16 , 17 ], and drug release controls intimal hyperplasia.…”

Section: Introductionmentioning

confidence: 99%

A Study of PLA Thin Film on SS 316L Coronary Stents Using a Dip Coating Technique

Macías-Naranjo,

Sánchez-Domínguez,

Rubio-Valle

et al. 2024

Polymers

View full text Add to dashboard Cite

The dip coating process is one of the recognized techniques used to generate polymeric coatings on stents in an easy and low-cost way. However, there is a lack of information about the influence of the process parameters of this technique on complex geometries such as stents. This paper studies the dip coating process parameters used to provide a uniform coating of PLA with a 4–10 µm thickness. A stainless-steel tube (AISI 316L) was laser-cut, electropolished, and dip-coated in a polylactic acid (PLA) solution whilst changing the process parameters. The samples were characterized to examine the coating’s uniformity, thickness, surface roughness, weight, and chemical composition. FTIR and Raman investigations indicated the presence of PLA on the stent’s surface, the chemical stability of PLA during the coating process, and the absence of residual chloroform in the coatings. Additionally, the water contact angle was measured to determine the hydrophilicity of the coating. Our results indicate that, when using entry and withdrawal speeds of 500 mm min−1 and a 15 s immersion time, a uniform coating thickness was achieved throughout the tube and in the stent with an average thickness of 7.8 µm.

show abstract

Drug-Eluting Stents: Technical and Clinical Progress

Cited by 16 publications

References 81 publications

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

Polymer-Drug Anti-Thrombogenic and Hemocompatible Coatings as Surface Modifications

A Study of PLA Thin Film on SS 316L Coronary Stents Using a Dip Coating Technique

Contact Info

Product

Resources

About